第一阶段研究SEA-CD70髓系恶性血液病

描述

这个试验将着眼于一种名为SEA-CD70的药物和没有阿扎胞苷,发现如果是安全的骨髓增生异常综合征(MDS)患者和急性髓系白血病(AML)。它将研究SEA-CD70找出它的副作用,如果它适合AML和MDS。有什么药物副作用除了治疗癌症。本研究将有六个组或“部分”。- Part A will find out how much SEA-CD70 should be given to patients. - Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with MDS. - Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with AML. - Part D will find out how much SEA-CD70 with azacitidine should be given to patients. - Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS that has not been treated. - Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS or AML.

资源和链接

电话:1 - 877 - mda - 6789

clinicaltrials.gov NCT没有:NCT04227847